Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
January 27, 2023 11:22 am ET
Delayed at least 20 minutes

Latest news, events & financials

January 27, 2023

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

January 25, 2023

Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility

January 25, 2023

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial

View all

February 02, 2023

Earnings

Merck & Co., Inc. Q4 2022 Earnings Call

Add to Calendar Webcast

March 06, 2023

Webcast

Merck & Co., Inc. Cardiovascular Investor Event at ACC.23/WCC

Add to Calendar

April 27, 2023

Earnings

Merck & Co., Inc. Q1 2023 Earnings Call

Add to Calendar

August 01, 2023

Earnings

Merck & Co., Inc. Q2 2023 Earnings Call

Add to Calendar

View all

3Q22 Merck Earnings Announcement
PDF

3Q22 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. Q4 2022 Earnings Call

Dial: (888) 769-8514 (U.S. Toll-Free) or (517) 308-9208 (International)

Access Code: 8206435

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Environmental, Social & Governance (ESG)

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2021/2022 ESG Progress Report

Download our ESG financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Merck’s Q2 2022 earnings report

Merck’s (NYSE: MRK) Q2 2022 results deliver robust sales growth and important clinical advancements. The company announced Q2 worldwide sales of $14.6 billion, an increase of 28% from Q2 2021. “I continue to be immensely proud of how the Merck team is performing in all facets of our business – scientifically, commercially and operationally,” said Robert […]

Next: Merck’s Q2 2022 earnings report